Sridhar Nimmagadda

List of Publications by Year
in descending order

75 papers	5,066 citations	94381 37 h-index	88593 70 g-index
80 all docs	80 docs citations	80 times ranked	7325 citing authors

#	Article	IF	Citations
1	First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2022, 63, 536-542.	2.8	56
2	PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model. Cancers, 2022, 14, 619.	1.7	4
3	Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. Journal of Medicinal Chemistry, 2021, 64, 4059-4070.	2.9	22
4	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]In–XYIMSR–01 for phase I regulatory approval. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 243-250.	0.5	2
5	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
6	Imaging PD-L1 expression in melanoma brain metastases. Journal of Nuclear Medicine, 2021, , jnumed.121.263209.	2.8	0
7	Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [124I]FIAU PET/CT. Molecular Imaging, 2020, 19, 153601212093687.	0.7	11
8	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers, 2020, 12, 3173.	1.7	36
9	Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells. ACS Applied Materials & Interfaces, 2019, 11, 7850-7861.	4.0	98
10	Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. Molecular Imaging, 2019, 18, 153601211985218.	0.7	52
11	Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. Molecular Pharmaceutics, 2019, 16, 2590-2604.	2.3	29
12	Translational Applications of Protein Structure Simulation: Predicting Phenotype of Missense Variants. Biophysical Journal, 2019, 116, 13a.	0.2	3
13	SNP2SIM: a modular workflow for standardizing molecular simulation and functional analysis of protein variants. BMC Bioinformatics, 2019, 20, 171.	1.2	7
14	Ovarian Cancer Targeted Theranostics. Frontiers in Oncology, 2019, 9, 1537.	1.3	27
15	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630.	3.9	94
16	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nature Communications, 2018, 9, 741.	5.8	238
17	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. Journal of Nuclear Medicine, 2018, 59, 486-493.	2.8	27
18	Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417.	2.8	23

#	Article	IF	Citations
19	Molecular Imaging of CXCL12 Promoter-driven HSV1-TK Reporter Gene Expression. Biotechnology and Bioprocess Engineering, 2018, 23, 208-217.	1.4	6
20	Peptide-Based ^{68}Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. Molecular Pharmaceutics, 2018, 15, 3946-3952.	2.3	102
21	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Modern Pathology, 2017, 30, 530-538.	2.9	92
22	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochemical and Biophysical Research Communications, 2017, 483, 258-263.	1.0	132
23	A PSMA-targeted theranostic agent for photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2017, 167, 111-116.	1.7	39
24	Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. Molecular Imaging, 2017, 16, 153601211771845.	0.7	47
25	In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent. Chemistry - A European Journal, 2017, 23, 14469-14475.	1.7	25
26	Imaging α4β2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. Molecular Imaging and Biology, 2017, 19, 280-288.	1.3	11
27	Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. PLoS ONE, 2017, 12, e0176958.	1.1	14
28	A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget, 2016, 7, 12344-12358.	0.8	32
29	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016, 7, 10215-10227.	0.8	158
30	PD-L1 Detection in Tumors Using [^{64}Cu]Atezolizumab with PET. Bioconjugate Chemistry, 2016, 27, 2103-2110.	1.8	128
31	Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chemical Biology, 2016, 11, 3214-3225.	1.6	364
32	[^{18}F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). Journal of Medicinal Chemistry, 2016, 59, 206-218.	2.9	37
33	Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. Journal of Nuclear Medicine, 2016, 57, 981-988.	2.8	28
34	Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. Nano Letters, 2016, 16, 2248-2253.	4.5	43
35	[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget, 2016, 7, 56471-56479.	0.8	49
36	Structural Characterization and in Vivo Evaluation of β-Hairpin Peptidomimetics as Specific CXCR4 Imaging Agents. Molecular Pharmaceutics, 2015, 12, 941-953.	2.3	13

#	ARTICLE	IF	CITATIONS
37	Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. Journal of Nuclear Medicine, 2015, 56, 628-634.	2.8	35
38	Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget, 2015, 6, 33733-33742.	0.8	44
39	The new frontiers of multimodality and multi-isotope imaging. , 2014, , .		1
40	Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nuclear Medicine and Biology, 2014, 41, 552-561.	0.3	25
41	Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochemical and Biophysical Research Communications, 2014, 443, 635-640.	1.0	9
42	The Intricate Role of CXCR4 in Cancer. Advances in Cancer Research, 2014, 124, 31-82.	1.9	496
43	^{64}Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer. Journal of Medicinal Chemistry, 2014, 57, 2657-2669.	2.9	103
44	Transforming Thymidine into a Magnetic Resonance Imaging Probe for Monitoring Gene Expression. Journal of the American Chemical Society, 2013, 135, 1617-1624.	6.6	80
45	Effect of Chelators on the Pharmacokinetics of ^{99m}Tc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). Journal of Medicinal Chemistry, 2013, 56, 6108-6121.	2.9	57
46	Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. AIDS Research and Human Retroviruses, 2013, 29, 1443-1450.	0.5	134
47	Molecular Imaging of Conscious, Unrestrained Mice with AwakeSPECT. Journal of Nuclear Medicine, 2013, 54, 969-976.	2.8	18
48	Distribution of Cell-Free and Cell-Associated HIV Surrogates in the Female Genital Tract After Simulated Vaginal Intercourse. Journal of Infectious Diseases, 2012, 205, 725-732.	1.9	28
49	Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging. Frontiers in Oncology, 2012, 2, 46.	1.3	5
50	Distribution of Cell-Free and Cell-Associated HIV Surrogates in the Colon After Simulated Receptive Anal Intercourse in Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 10-17.	0.9	34
51	PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy. ACS Nano, 2012, 6, 7752-7762.	7.3	95
52	Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer. PLoS ONE, 2012, 7, e44078.	1.1	125
53	Effects of Recombinant Human Thyroid-Stimulating Hormone Superagonists on Thyroidal Uptake of 18F-Fluorodeoxyglucose and Radioiodide. Thyroid, 2011, 21, 783-792.	2.4	9
54	Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostateâ€Specific Membrane Antigen. Angewandte Chemie - International Edition, 2011, 50, 9167-9170.	7.2	106

#	ARTICLE	IF	CITATIONS
55	Metabolic Signatures Imaged in Cancer-Induced Cachexia. Cancer Research, 2011, 71, 6948-6956.	0.4	26
56	2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. Clinical Cancer Research, 2011, 17, 7645-7653.	3.2	331
57	CXCR4-Based Imaging Agents. Journal of Nuclear Medicine, 2011, 52, 1665-1669.	2.8	39
58	Imaging CXCR4 Expression in Human Cancer Xenografts: Evaluation of Monocyclam ^{64}Cu-AMD3465. Journal of Nuclear Medicine, 2011, 52, 986-993.	2.8	75
59	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. Oncotarget, 2011, 2, 59-68.	0.8	40
60	Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma. Cancer Research, 2010, 70, 4045-4053.	0.4	48
61	^{68}Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer. Journal of Medicinal Chemistry, 2010, 53, 5333-5341.	2.9	196
62	Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100 Positron Emission Tomography. Cancer Research, 2010, 70, 3935-3944.	0.4	118
63	Bacterial Thymidine Kinase as a Non-Invasive Imaging Reporter for Mycobacterium tuberculosis in Live Animals. PLoS ONE, 2009, 4, e6297.	1.1	59
64	Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT. Journal of Nuclear Medicine, 2009, 50, 1124-1130.	2.8	64
65	Herpes simplex virus thymidine kinase imaging in mice with (1-(2â€²-deoxy-2â€²-[18F]fluoro-1-Î²-D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2â€²-deoxy-2â€²-[18F]fluoro-1-Î²-D-arabinofuranosyl)-5-uracil). European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1987-1993.	3.3	6
66	Pharmacodynamic Markers for Choline Kinase Down-regulation in Breast Cancer Cells. Neoplasia, 2009, 11, 477-484.	2.3	23
67	The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews, 2008, 27, 575-587.	2.7	18
68	Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy. Seminars in Radiation Oncology, 2008, 18, 136-148.	1.0	27
69	Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. Journal of Medicinal Chemistry, 2008, 51, 7933-7943.	2.9	180
70	Imaging Virus-Associated Cancer. Current Pharmaceutical Design, 2008, 14, 3048-3065.	0.9	3
71	Detection of Dose Response in Chronic Doxorubicin-Mediated Cell Death with Cardiac Technetium 99m Annexin V Single-Photon Emission Computed Tomography. Molecular Imaging, 2008, 7, 7290.2008.00015.	0.7	36
72	Biodistribution, PET, and Radiation Dosimetry Estimates of HSV-tk Gene Expression Imaging Agent 1-(2'-Deoxy-2'-18F-Fluoro-Â-D-Arabinofuranosyl)-5-Iodouracil in Normal Dogs. Journal of Nuclear Medicine, 2007, 48, 655-660.	2.8	17

#	Article	IF	Citations
73	Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT. PLoS ONE, 2007, 2, e1007.	1.1	86
74	Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. Journal of Nuclear Medicine, 2005, 46, 1916-22.	2.8	12
75	A Convenient Method of Synthesis of <i>Bis</i>-Indolylmethanes: Indium Trichloride Catalyzed Reactions of Indole with Aldehydes and Schiff's Bases. Synthetic Communications, 2000, 30, 1609-1614.	1.1	174